These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10382846)

  • 1. Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy.
    Brooks RC; Carnochan P; Vollano JF; Powell NA; Zweit J; Sosabowski JK; Martellucci S; Darkes MC; Fricker SP; Murrer BA
    Nucl Med Biol; 1999 May; 26(4):421-30. PubMed ID: 10382846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic activity, tumor accumulation, and tissue distribution of ruthenium-103-labeled bleomycin.
    Stern PH; Helpern SE; Hagan PL; Howell SB; Dabbs JE; Gordon RM
    J Natl Cancer Inst; 1981 May; 66(5):807-11. PubMed ID: 6164811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Labelled bleomycin as a tumour-localizing agent. II. The effect of dose loading of the different forms of 57Cobalt-bleomycin A2, B2, and pepleomycin on the tissue distribution and tumour uptake in tumour-bearing rats.
    Vos CM; Westera G
    Eur J Nucl Med; 1982; 7(2):92-4. PubMed ID: 6177534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 105Rh as a potential radiotherapeutic agent.
    Grazman B; Troutner DE
    Int J Rad Appl Instrum A; 1988; 39(3):257-60. PubMed ID: 2836343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 111In-bleomycin for combining radiotherapy and chemotherapy on glioma-bearing mice.
    Hou DY; Hoch H; Johnston GS; Tsou KC; Farkas RJ; Miller EE
    J Surg Oncol; 1985 Jun; 29(2):71-7. PubMed ID: 2417054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of 111In-bleomycin in vivo--properties compared with 57Co-bleomycin.
    Hou DY; Hoch H; Johnston GS; Tsou KC; Farkas RJ; Miller EE
    Eur J Nucl Med; 1983; 8(12):535-40. PubMed ID: 6199207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor effect of targeted nanoliposomal bleomycin.
    Chiani M; Azadmanesh K; Shokrgozar MA; Mehrabi MR; Akbarzadeh A; Norouzian D
    Chem Biol Drug Des; 2017 Nov; 90(5):953-961. PubMed ID: 28498511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new 111In-bleomycin complex for combined radiotherapy and chemotherapy.
    Hou DY; Hoch H; Johnston GS; Tsou KC; Jones AE; Farkas RJ; Miller EE; Larson SM
    J Surg Oncol; 1985 Jun; 29(2):91-8. PubMed ID: 2417055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhodium-105 tetrathioether complexes: radiochemistry and initial biological evaluation.
    Goswami N; Higginbotham C; Volkert W; Alberto R; Nef W; Jurisson S
    Nucl Med Biol; 1999 Nov; 26(8):951-7. PubMed ID: 10708310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells.
    Saini J; Bansal V; Chandra A; Madan J; Jain UK; Chandra R; Jain SM
    Colloids Surf B Biointerfaces; 2014 Jun; 118():101-10. PubMed ID: 24732397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Rh-105 complex of tetrathiacyclohexadecane diol with potential for formulating bifunctional chelates.
    Venkatesh M; Goswami N; Volkert WA; Schlemper EO; Ketring AR; Barnes CL; Jurisson S
    Nucl Med Biol; 1996 Jan; 23(1):33-40. PubMed ID: 9004912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis.
    Harrison JH; Lazo JS
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1052-8. PubMed ID: 2462625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of 105Rh-EDTMP and its bone accumulation.
    Ando A; Ando I; Tonami N; Kinuya S; Okamoto N; Sugimoto M; Fukuda N; Matsumoto S
    Appl Radiat Isot; 2000 Feb; 52(2):211-5. PubMed ID: 10697730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution of model 105Rh-labeled tetradentate thiamacrocycles in rats.
    Li N; Struttman M; Higginbotham C; Grall AJ; Skerlj JF; Vollano JF; Bridger SA; Ochrymowycz LA; Ketring AR; Abrams MJ; Volkert WA
    Nucl Med Biol; 1997 Jan; 24(1):85-92. PubMed ID: 9080479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular distribution of 57Co-bleomycin.
    Konings AW; Rasker JJ; Posthuma GA
    Curr Top Radiat Res Q; 1978 Jan; 12(1-4):497-512. PubMed ID: 76527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new tumor imaging agent--111In-bleomycin complex. Comparison with 67Ga-citrate and 57Co-bleomycin in tumor-bearing animals.
    Hou DY; Hoch H; Johnston GS; Tsou KC; Jones AE; Miller EE; Larson SM
    J Surg Oncol; 1984 Nov; 27(3):189-95. PubMed ID: 6208427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug distribution and antitumor effect of bleomycin incorporated in poly DL-lactic acid in rats].
    Kumanohoso T; Natsugoe S; Tokuda K; Shimada M; Sagara M; Shinkawa T; Nakamura K; Yamada K; Fukuzaki H; Aikou T
    Gan To Kagaku Ryoho; 1994 Sep; 21(13):2248-50. PubMed ID: 7524449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic comparison of radiolabeled bleomycin and bleomycin-glucuronide labeled with 99mTc.
    Koçan F; Avcıbaşı U; Unak P; Müftüler FZ; Içhedef CA; Demiroğlu H; Gümüşer FG
    Cancer Biother Radiopharm; 2011 Oct; 26(5):573-84. PubMed ID: 21950554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of bleomycin adsorbed on to activated carbon particles by regional lymph nodes of the esophagus in dogs.
    Shimada M; Aikou T; Natsugoe S; Shimazu H; Nakamura K
    Anticancer Drug Des; 1993 Aug; 8(4):249-55. PubMed ID: 7694587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labelling of bleomycin with cobalt-57, indium-111, technetium-99m, mercury-197, lead-203, and copper-67.
    van de Poll MA; Versluis A; Rasker JJ; Jurjens H; Woldring MG
    Nuklearmedizin; 1976 Apr; 15(2):86-90. PubMed ID: 58409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.